Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.68 |
| ▸ | MEP1B | Q16820 | 10/20 | 0.58 |
| ▸ | MMP2 | P08253 | 7/20 | 0.58 |
| ▸ | MMP14 | P50281 | 7/20 | 0.58 |
| ▸ | MMP13 | P45452 | 5/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.58 |
| ▸ | MMP9 | P14780 | 5/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14045869 | 0.81 | ALDH1A1 (0.49) | MMP1MEP1BMMP2MMP14MMP13 | |
| SCHEMBL5182288 | 0.79 | MEP1B (0.69) | MMP1MEP1BMMP2MMP14MMP13 | |
| SCHEMBL14052271 | 0.78 | ALDH1A1 (0.54) | — | |
| SCHEMBL4919261 | 0.78 | HDAC6 (0.79) | — | |
| SCHEMBL23343636 | 0.77 | CA12 (0.60) | — | |
| SCHEMBL7413923 | 0.77 | MMP2 (0.72) | MMP1MEP1BMMP2MMP14MMP13 | |
| SCHEMBL2553981 | 0.75 | MEP1B (0.81) | MMP1MEP1BMMP2MMP14MMP13 | |
| SCHEMBL7410575 | 0.75 | MEP1B (0.91) | MMP1MEP1BMMP2MMP14MMP13 | |
| SCHEMBL23052429 | 0.74 | LMNA (0.51) | — | |
| SCHEMBL7414039 | 0.73 | MMP1 (1.00) | MMP1MEP1BMMP2MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | claimed |
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2008-10-30 | — | — | US | disclosed |
| EP-1796681-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | Genmedica Therapeutics SL (ES) | 2007-06-20 | — | — | EP | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | GENMEDICA THERAPEUTICS SL (ES) | 2007-03-22 | — | — | US | disclosed |
| WO-2006013209-A2 | COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF | GENMEDICA THERAPEUTICS SL (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269282-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | MMP1 387/4885MEP1B 3107/4885MMP2 428/4885 |
| US-20070066646-A1 | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof | AOC2, AOC3, AOC1 | MMP1 510/4885MEP1B 3118/4885MMP2 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.